Anti-hypertension effect and safety of nitrendipine/atenolol

MA Li-yuan; WANG Wen; CHEN Wei-wei; LIU Ming-bo; DENG Qing; LIU Li-sheng

doi:10.3969/j.1674-4055.2014.02.07

Abstract：Objective To observe the curative effect and safety of nitrendipine/atenolol in hypertensive patients with cardiovascular risk factors, and observe the influence of nitrendipine/atenolol on ambulatory blood pressure (BP). Methods The study was a multicenter randomized controlled clinical trial. The hypertensive patients with cardiovascular risk factors aged from 18 to 79 were chosen into the trial after informed consent. In 2-w run-in period, all patients stopped their anti-hypertension durgs. After 2 w, the patients with SBP from 140 mmHg to 179 mmHg and/or DBP from 90 mmHg to 109 mmHg were randomly divided into nitrendipine/atenolol group (group A) and amlodipine besylate group (group B). The target BP was<140/90 mmHg, and during follow-up period (6 months), the drug dose would be increased or other anti-hypertensive agents would be applied according to BP target. The patients were given a 24-h ambulatory blood pressure monitoring (ABPM) respectively at baseline and after treatment for 4 w and 6 months. The incidence of adverse events was observed at any time. Results There were totally 207 hypertensive patients included from 7 national cooperation centers. After treatment for 1 month, SBP and DBP decreased significantly in 2 groups and the difference was significant compared with before treatment (P<0.01), and this trend was continued to the end of the trial. After treatment for 6 months, BP decreased by 18.9/9.2 mmHg in group A and by 18.2/9.9 mmHg in group B. after tratmetn for 4 w and 6 months, 24-h ABPM showed that daytime and nighttime BP decreased significantly in 2 groups. BP control rate reached to 50%after treatment for 1 month and reached to 77%after treatment for 6 months. There were no adverse events reported during the trial. Conclusion Nitrendipine/atenolol can rapidly and effectively reduce BP level in patients with high-risk hypertension, and it has no impact on glucolipid metabolism.